Average private biopharma M&A upfront cash and equity worldwide 2008-2020
In 2020, 264 million U.S. dollars were paid in upfront cash and equity for mergers and acquisitions worldwide involving companies developing biopharma therapeutics and tech platforms. This statistic illustrates the average value of private biopharma M&A upfront cash and equity worldwide from 2008 to 2020.